Emergent wins an additional $ 23 million vaccine manufacturing contract
(Reuters) – Emergent BioSolutions Inc announced late Sunday that a major U.S. agency had increased an order related to the manufacture of Johnson & Johnson’s (NYSE 🙂 COVID-19 vaccine by $ 23 million.
The amount will be used to purchase biologics specific to J & J’s vaccine and to support the potential expansion of production at the company’s Baltimore Bayview facility, the company said in a statement.
Emergent also said it will agree to a cessation of manufacturing AstraZeneca (NASDAQ 🙂 Plc’s COVID-19 vaccine in bulk.
Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. As a result, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.
Fusion Media or any person involved with Fusion Media assumes no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.